News Quantified

DRRX – durect corporation (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

0.0%

BEAT

-0.3%

IN-LINE

0.0%

BEAT

Form 4 DURECT CORP For: Sep 10 Filed by: Farfel Gail M

Form 4 DURECT CORP For: Sep 09 Filed by: BROWN JAMES E

Form 4 DURECT CORP For: Sep 10 Filed by: Robertson Judith J.

Form 4 DURECT CORP For: Sep 09 Filed by: GARCIA PETER S

Form 4 DURECT CORP For: Sep 09 Filed by: Maderis Gail J

Top News Gainers

5/7 DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial 23.8%

12/21 DURECT Co. (NASDAQ: DRRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 21.2%

8/1 Form 8-K DURECT CORP For: Aug 01 19.0%

1/17 Biopharma Durect says FDA committee ended meeting with split vote on post-surgical pain treatment [MarketWatch] 16.7%

6/20 DURECT Announces $15 Million Registered Direct Offering 16.7%

3/3 Q4/2019 12/31/2019 EPS -0.020 ZacksConsensus -0.010 ActVsEst (0.010) - Miss 12.8%

6/18 DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial 10.2%

3/5 Novartis Price Fixing, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] 8.5%

10/2 DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain 7.1%

12/30 3 Healthcare Stocks With Huge FDA Decisions in January [Yahoo! Finance News] 6.3%

Top News Decliners

1/2 DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis -35.3%

6/27 DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter -22.8%

7/22 DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product -19.1%

7/17 Form 8-K DURECT CORP For: Jul 17 -8.5%

3/7 Edited Transcript of DRRX earnings conference call or presentation 3-Mar-20 9:30pm GMT [Yahoo! Finance News] -8.0%

5/3 Form 8-K DURECT CORP For: May 03 -7.6%

9/27 DURECT (DRRX) Investor Presentation - Slideshow [Seeking Alpha] -7.1%

11/12 DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting® -7.0%

5/9 DURECT Co. (NASDAQ: DRRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.50 price target on the stock. -6.9%

4/15 DURECT Co. (NASDAQ: DRRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day